CAPREOMYCIN

US Previously Marketed

First approved in 1971

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050095s062lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/20154709

Capreomycin is an antibiotic, which is used in combination other antituberculosis drugs fro the treatment of pulmonary infections caused by capreomycin-susceptible strains of M. tuberculosis when the primary agents (isoniazid, rifampin, ethambutol, aminosalicylic acid, and streptomycin) have been ineffective or cannot be used because of toxicity or the presence of resistant tubercle bacilli. Little is known about capreomycin's exact mechanism of action, but it is thought to inhibit protein synthesis by binding to the 70S ribosomal unit. Capreomycin also binds to components in the bacterial cell which result in the production of abnormal proteins.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
70S ribosome 16 Target ID: CHEMBL2363965 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20154709	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pulmonary infections 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050095s062lbl.pdf	Curative		Approved 8583	CAPASTAT SULFATE Approved Use Capastat Sulfate, which is to be used concomitantly with other appropriate antituberculosis agents, is indicated in pulmonary infections caused by capreomycin-susceptible strains of M. tuberculosis when the primary agents (isoniazid, rifampin, ethambutol, aminosalicylic acid, and streptomycin) have been ineffective or cannot be used because of toxicity or the presence of resistant tubercle bacilli. Susceptibility studies should be performed to determine the presence of a capreomycin-susceptible strain of M. tuberculosis. Launch Date 1971

PubMed

Title	Date	PubMed
Capreomycin--a polypeptide antitubercular antibiotic with unusual binding properties toward copper(II).	2012-01	22112847
Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2'-O-methylations in 16S and 23S rRNAs.	2006-07-21	16857584
Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.	2005-08	16048924
Capreomycin is active against non-replicating M. tuberculosis.	2005-04-01	15804353
Capreomycin in the treatment of atypical mycobacterial disease in HIV-positive patients.	2002-07	12172753
Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis.	1998-05	9593173

Patents

Sample Use Guides

In Vivo Use Guide

Intravenously: Capastat Sulfate (Capreomycin for Injection) should be diluted in 100 mL of 0.9% Sodium Chloride Injection and administered over 60 minutes. Intramuscularly — Reconstituted Capastat Sulfate should be given by deep intramuscular injection into a large muscle mass, since superficial injection may be associated with increased pain and the development of sterile abscesses. For administration of a 1-g dose, the entire contents of the vial should be given. For doses lower than 1 g, the following dilution table may be used.

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Mixture Created by `admin` on `Mon Mar 31 18:05:28 GMT 2025` Edited by `admin` on `Mon Mar 31 18:05:28 GMT 2025`
Record UNII	232HYX66HC
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CAPREOMYCIN

Official Name

English

CAPASTAT

Preferred Name

English

CAPREOMYCIN [HSDB]

Common Name

English

CAPREOMICIN

Common Name

English

Capreomycin [WHO-DD]

Common Name

English

CAPREOMYCIN [MI]

Common Name

English

CAPOSTATIN

Common Name

English

capreomycin [INN]

Common Name

English

CAPREOMYCIN [VANDF]

Common Name

English

CAPROMYCIN

Common Name

English

Classification Tree Code System Code

WHO-VATC

QJ04AB30